Interaction between Comorbidities and Use of Disease Modifying Treatment in Impact on Disability Status in a Regional Multiple Sclerosis Registry

Author(s):  
Lindsay Lucas
2021 ◽  
Vol 7 (2) ◽  
pp. 205521732110155
Author(s):  
Marinos G Sotiropoulos ◽  
Hrishikesh Lokhande ◽  
Brian C Healy ◽  
Mariann Polgar-Turcsanyi ◽  
Bonnie I Glanz ◽  
...  

Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes. Methods Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes. Results Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking. Conclusions Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.


2013 ◽  
Vol 124 (11) ◽  
pp. e197
Author(s):  
L. Leocani ◽  
M. Bianco ◽  
G.Di Maggio ◽  
S. Medaglini ◽  
J. Gonzalez-Rosa ◽  
...  

2013 ◽  
Vol 20 (6) ◽  
pp. 739-746 ◽  
Author(s):  
Stella E Hughes ◽  
Tim Spelman ◽  
Orla M Gray ◽  
Cavit Boz ◽  
Maria Trojano ◽  
...  

Background: Several studies have shown that pregnancy reduces multiple sclerosis (MS) relapses, which increase in the early postpartum period. Postpartum relapse risk has been predicted by pre-pregnancy disease activity in some studies. Objective: To re-examine effect of pregnancy on relapses using the large international MSBase Registry, examining predictors of early postpartum relapse. Methods: An observational case–control study was performed including pregnancies post-MS onset. Annualised relapse rate (ARR) and median Expanded Disability Status Scale (EDSS) scores were compared for the 24 months pre-conception, pregnancy and 24 months postpartum periods. Clustered logistic regression was used to investigate predictors of early postpartum relapses. Results: The study included 893 pregnancies in 674 females with MS. ARR (standard error) pre-pregnancy was 0.32 (0.02), which fell to 0.13 (0.03) in the third trimester and rose to 0.61 (0.06) in the first three months postpartum. Median EDSS remained unchanged. Pre-conception ARR and disease-modifying treatment (DMT) predicted early postpartum relapse in a multivariable model. Conclusion: Results confirm a favourable effect on relapses as pregnancy proceeds, and an early postpartum peak. Pre-conception DMT exposure and low ARR were independently protective against postpartum relapse. This novel finding could provide clinicians with a strategy to minimise postpartum relapse risk in women with MS planning pregnancy.


Sign in / Sign up

Export Citation Format

Share Document